NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q2 2024 NPCE stock results show that NeuroPace beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
NPCE Stock Earnings: NeuroPace Meets EPS, Beats Revenue for Q1 2024 NPCE stock results show that NeuroPace met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q4 2023 NPCE stock results show that NeuroPace beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio Stocks for financial freedom are generational companies that are well-run, growing fast, and focused on the future.
Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position Cantor Fitzgerald initiated coverage on NeuroPace Inc (
NASDAQ: NPCE ), a commercial-stage medical device company focused on drug-resistant epilepsy treatment through the company's responsive neurostimulation device (RNS).
Earnings Scheduled For November 6, 2023 Companies Reporting Before The Bell • Kosmos Energy (
NYSE:KOS ) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Earnings Scheduled For March 5, 2024 Companies Reporting Before The Bell • NIO (
NYSE:NIO ) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
Top 5 Health Care Stocks That May Fall Off A Cliff The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
